SAN FRANCISCO (CN) - A federal judge on Thursday finalized two class action settlements worth $270 million, ending four years of litigation over an alleged antitrust conspiracy to keep a generic form of the Lidoderm pain patch off the market.
Under the terms of two deals approved Thursday, drug makers Endo, Teikoku and Watson will pay $166 million to a class of direct buyer plaintiffs and $104.7 million to a class of end-payor plaintiffs.
The pharmaceutical firms were sued in 2014; accused of striking an anti-competitive settlement deal in May 2012 that blocked a cheaper generic version of Lidoderm from hitting the market for more than a year.
As part of that settlement, Watson agreed to delay launching its generic patch until September 2013 and to drop a pending patent suit against Endo and Teikoku, creators of the original Lidoderm painkiller. In exchange, Endo gave Watson $96 million worth of Lidoderm patches and promised not to launch its own generic patch until 7 ½ months after Watson’s generic hit the market, according to the plaintiffs.
Last year, Endo submitted to an injunction barring it from striking anti-competitive pacts with generic drug makers to resolve antitrust claims with the Federal Trade Commission.
In February 2017, U.S. District Judge William Orrick certified two separate classes of plaintiffs — one consisting of direct purchasers of Lidoderm and another group called end-payor plaintiffs, whose financial harm was more indirect.
For the $166 million settlement with direct buyers, Endo will pay $60 million, Watson will pay $71 million, and Teikoku will forfeit $35 million.
For the separate $104.7 million deal with end-payor plaintiffs, Watson will pay $41 million, Endo will pay $40 million, and Teikoku will cover a smaller share of $23 million.
On Thursday, Orrick also approved attorneys' fees awards for each class. The judge awarded $47.3 million in attorneys' fees and costs to lawyers for the direct purchaser plaintiffs.
He also approved a fees award of $34.9 million for the end-payor class, finding it justified to apply a 1.37 multiplier to the lawyers' billable hours because they "obtained a significant benefit" for the class. Orrick also approved another $3.9 million in reimbursement of litigation costs for the end-payor class.
Peter Kohn, lead class counsel for the direct purchaser class, and Daniel Girard, lead class counsel for the end-payor class, did not immediately return emails seeking comment after business hours Thursday.
Kohn is with Faruqi & Faruqi in Jenkintown, Pennsylvania. Girard is with Girard Gibbs in San Francisco.
Follow @NicholasIovino
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
